It is very uncertain whether sunitinib changes progression‐free survival (absolute effect size estimates based on… compared with IMA901 + sunitinib (targeted agent versus tumour vaccine + targeted… (very low certainty).
Sunitinib probably leads to higher progression‐free survival(absolute effect size estimates based on… compared with avelumab + axitinib (targeted agent versus immunotherapy + targeted… (moderate certainty).
Sunitinib probably leads to higher progression‐free survival(absolute effect size estimates based on… compared with pembrolizumab + axitinib (targeted agent versus immunotherapy +… (moderate certainty).
Sunitinib may leads to higher progression‐free survival(absolute effect size estimates based on… compared with atezolizumab + bevacizumab (targeted agent versus immunotherapy +… (low certainty).
Sunitinib probably leads to lower progression‐free survival (absolute effect size estimates based on… compared with interferon‐α (IFN‐α) (targeted agent versus classic immunotherapy) (moderate certainty).
Sunitinib probably leads to lower progression‐free survival (absolute effect size estimates based on… compared with everolimus (targeted agent versus targeted agent) (moderate certainty).
It is very uncertain whether sunitinib changes progression‐free survival (absolute effect size estimates based on… compared with atezolizumab (targeted therapy versus immunotherapy) (very low certainty).
Sunitinib may leads to higher progression‐free survival (absolute effect size estimates based on… compared with nivolumab + ipilimumab (targeted agent versus combinations of… (low certainty).
Sorafenib showed no clear difference in progression‐free survival (absolute effect size estimates based on… compared with sunitinib (targeted agent versus targeted agent) (low certainty).
Pazopanib showed no clear difference in progression‐free survival (absolute effect size estimates based on… compared with sunitinib (targeted agent versus targeted agent) (low certainty).